363 related articles for article (PubMed ID: 15010843)
1. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
3. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Podewski EK; Hilfiker-Kleiner D; Hilfiker A; Morawietz H; Lichtenberg A; Wollert KC; Drexler H
Circulation; 2003 Feb; 107(6):798-802. PubMed ID: 12591746
[TBL] [Abstract][Full Text] [Related]
5. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.
Park ES; Kim H; Suh JM; Park SJ; You SH; Chung HK; Lee KW; Kwon OY; Cho BY; Kim YK; Ro HK; Chung J; Shong M
Mol Endocrinol; 2000 May; 14(5):662-70. PubMed ID: 10809230
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Banes AK; Shaw S; Jenkins J; Redd H; Amiri F; Pollock DM; Marrero MB
Am J Physiol Renal Physiol; 2004 Apr; 286(4):F653-9. PubMed ID: 14678947
[TBL] [Abstract][Full Text] [Related]
7. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor.
Ali S; Nouhi Z; Chughtai N; Ali S
J Biol Chem; 2003 Dec; 278(52):52021-31. PubMed ID: 14522994
[TBL] [Abstract][Full Text] [Related]
8. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription.
Berchtold S; Volarevic S; Moriggl R; Mercep M; Groner B
Mol Endocrinol; 1998 Apr; 12(4):556-67. PubMed ID: 9544991
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
11. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling.
Minoo P; Zadeh MM; Rottapel R; Lebrun JJ; Ali S
Blood; 2004 Feb; 103(4):1398-407. PubMed ID: 14551136
[TBL] [Abstract][Full Text] [Related]
12. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
Tomic S; Chughtai N; Ali S
Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
[TBL] [Abstract][Full Text] [Related]
13. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
Yoshikawa H; Matsubara K; Qian GS; Jackson P; Groopman JD; Manning JE; Harris CC; Herman JG
Nat Genet; 2001 May; 28(1):29-35. PubMed ID: 11326271
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Janus kinase 2 by p53 in ovarian cancer cells.
Reid T; Jin X; Song H; Tang HJ; Reynolds RK; Lin J
Biochem Biophys Res Commun; 2004 Aug; 321(2):441-7. PubMed ID: 15358195
[TBL] [Abstract][Full Text] [Related]
15. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia.
Kim HY; Park EJ; Joe EH; Jou I
J Immunol; 2003 Dec; 171(11):6072-9. PubMed ID: 14634121
[TBL] [Abstract][Full Text] [Related]
16. Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway.
Flores-Morales A; Fernández L; Rico-Bautista E; Umana A; Negrín C; Zhang JG; Norstedt G
Mol Endocrinol; 2001 Sep; 15(9):1471-83. PubMed ID: 11518796
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
Cheng J; Zhang D; Zhou C; Marasco WA
Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells.
Burke WM; Jin X; Lin HJ; Huang M; Liu R; Reynolds RK; Lin J
Oncogene; 2001 Nov; 20(55):7925-34. PubMed ID: 11753675
[TBL] [Abstract][Full Text] [Related]
19. A new protein containing an SH2 domain that inhibits JAK kinases.
Endo TA; Masuhara M; Yokouchi M; Suzuki R; Sakamoto H; Mitsui K; Matsumoto A; Tanimura S; Ohtsubo M; Misawa H; Miyazaki T; Leonor N; Taniguchi T; Fujita T; Kanakura Y; Komiya S; Yoshimura A
Nature; 1997 Jun; 387(6636):921-4. PubMed ID: 9202126
[TBL] [Abstract][Full Text] [Related]
20. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells.
Flowers LO; Subramaniam PS; Johnson HM
Oncogene; 2005 Mar; 24(12):2114-20. PubMed ID: 15688010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
